TG Therapeutics TGTX Product — Accounts Payable And Accrued Liabilities Current

Similar metrics at other companies

CBREAccounts Payable and Accrued Liabilities, Current

$4.73B+20.0%

EPDAccrued product payables

$11.18B+18.7%

AESAccounts Payable

$1.96B+18.5%

DOWAccounts Payable

$4.77B-3.2%

EFXAccounts Payable

$158.4M-8.1%

DELLAccounts Payable

$45.26B+78.6%

Questions, answered.

What is TG Therapeutics's product — accounts payable and accrued liabilities current?

TG Therapeutics (TGTX) reported product — accounts payable and accrued liabilities current of $59M in Q1 2026.

What does product — accounts payable and accrued liabilities current mean?

This represents the short-term obligations the company owes to suppliers and service providers specifically related to its product operations. It encompasses trade payables and accrued expenses such as distribution costs or manufacturing fees. This metric provides insight into the company's short-term operational liabilities and cash management strategy.